<DOC>
	<DOCNO>NCT00551772</DOCNO>
	<brief_summary>SB-742457 5HT6 receptor antagonist development symptomatic treatment mild moderate Alzheimer 's disease . To date , clinical trial conduct use capsule formulation SB-742457 . However , intend conduct future study tablet formulation . The aim study assess pharmacokinetic profile SB-742457 major metabolite follow single dos capsule tablet formulation .</brief_summary>
	<brief_title>A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Men surgically sterile postmenopausal woman Healthy judge responsible physician . No clinically significant abnormality identify medical lab evaluation . BMI 18.5 32.0 kg/m2 Exclusion criterion : A positive prestudy urine screen drug abuse Abuse alcohol Subjects smoke 10 cigarette equivalent day . Use prescription drug well herbal dietary supplement within 7 day prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Where participation study would result donation blood excess 500ml within 56 day period . Has history presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . The subject receive investigational drug participate another research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Known suspected history seizure , include febrile seizure , unexplained recent loss consciousness history significant head trauma loss consciousness .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Bio-availability , healthy elderly volunteer</keyword>
</DOC>